Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study

Côme Lepage, Jean-Marc Phelip, Astrid Lièvre, Karine Le-Malicot, Laëtitia Dahan, David Tougeron, Christos Toumpanakis, Frédéric Di-Fiore, Catherine Lombard‐Bohas, Ivan Borbath, Romain Coriat, Thierry Lecomte, Rosine Guimbaud, Caroline Pétorin, Jean-Louis Legoux, Pierre Michel, J.Y. Scoazec, Denis Smith, Thomas Walter